RESEARCH

Low serum 1,25(OH)$_2$D$_3$ in end-stage renal disease: is reduced 1$\alpha$-hydroxylase the only problem?

Sharon A Huish$^{1,2,3}$, Carl Jenkinson$^4$, Janet A Dunn$^2$, David J Meredith$^3$, Rosemary Bland$^2$ and Martin Hewison$^4$

$^1$University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, UK
$^2$The University of Warwick, Coventry, UK
$^3$Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
$^4$The University of Birmingham, Birmingham, UK

Correspondence should be addressed to M Hewison: M.Hewison@bham.ac.uk

Abstract

Low serum 1,25-dihydroxyvitamin D (1,25(OH)$_2$D) in end-stage renal disease (ESRD) is considered a consequence of elevated fibroblast growth factor 23 (FGF23) and concomitant reduced activity of renal 1$\alpha$-hydroxylase (CYP27B1). Current ESRD treatment strategies to increase serum calcium and suppress secondary hyperparathyroidism involve supplementation with vitamin D analogues that circumvent 1$\alpha$-hydroxylase. This overlooks the potential importance of 25-hydroxyvitamin D (25(OH)D) deficiency as a contributor to low serum 1,25(OH)$_2$D. We investigated the effects of vitamin D (cholecalciferol) supplementation (40,000 IU for 12 weeks and maintenance dose of 20,000 IU fortnightly), on multiple serum vitamin D metabolites (25(OH)D, 1,25(OH)$_2$D$_3$ and 24,25(OH)$_2$D$_3$) in 55 haemodialysis patients. Baseline and 12 month data were compared using related-samples Wilcoxon signed rank test. All patients remained on active vitamin D analogues as part of routine ESRD care. 1,25(OH)$_2$D$_3$ levels were low at baseline (normal range: 60–120 pmol/L). Cholecalciferol supplementation normalised both serum 25(OH)D and 1,25(OH)$_2$D$_3$. Median serum 25(OH)D increased from 35.1 nmol/L (IQR: 23.0–47.5 nmol/L) to 119.9 nmol/L (IQR: 99.5–143.3 nmol/L) ($P < 0.001$). Median serum 1,25(OH)$_2$D$_3$ and 24,25(OH)$_2$D$_3$ increased from 48.3 pmol/L (IQR: 35.9–57.9 pmol/L) and 3.8 nmol/L (IQR: 2.3–6.0 nmol/L) to 96.2 pmol/L (IQR: 77.1–130.6 pmol/L) and 12.3 nmol/L (IQR: 9–16.4 nmol/L), respectively ($P < 0.001$). A non-significant reduction in daily active vitamin D analogue dose occurred, 0.94 µmcg at baseline to 0.77 µmcg at 12 months ($P = 0.73$). The ability to synthesise 1,25(OH)$_2$D$_3$ in ESRD is maintained but is substrate dependent, and serum 25(OH)D was a limiting factor at baseline. Therefore, 1,25(OH)$_2$D$_3$ deficiency in ESRD is partly a consequence of 25(OH)D deficiency, rather than solely due to reduced 1$\alpha$-hydroxylase activity as suggested by current treatment strategies.

Introduction

The kidney is the major site for synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)$_2$D). The enzyme that synthesises 1,25(OH)$_2$D from precursor 25-hydroxyvitamin D (25(OH)D), 1$\alpha$-hydroxylase (CYP27B1), is expressed primarily in the renal proximal tubule (1, 2), and is positively and negatively regulated by parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), respectively (3). While the kidney has...
a central role in 1,25(OH)₂D production, 1α-hydroxylase activity has been found in several other cell types throughout the body including the parathyroid glands, testes, skin, placenta, decidua and macrophages (4, 5). The precise contribution of these extra-renal sites of 1α-hydroxylase activity to circulating levels of 1,25(OH)₂D remains unclear.

Serum 1,25(OH)₂D concentration decreases as chronic kidney disease (CKD) progresses, as a consequence of reduced renal 1,25(OH)₂D synthesis (6, 7). This, in turn, contributes to the lack of feedback regulation of PTH that can lead to secondary hyperparathyroidism in CKD, notably in end-stage renal disease (ESRD). To address this, patients with ESRD are routinely prescribed either 1,25(OH)₂D (calcitriol), synthetic analogues of 1,25(OH)₂D (e.g. paricalcitol) or vitamin D analogues that do not require the action of 1α-hydroxylase (e.g. alfalcaldiol). However, patients with ESRD also have low serum levels of the substrate for 1α-hydroxylase (25(OH)D), with reported prevalence rates of 25(OH)D deficiency of up to 95% (8, 9). The significance of this finding is unclear but low serum 25(OH)D may also contribute to impaired feedback regulation of PTH (10). 25(OH)D is a substrate for both activating and catabolic pathways; thus in addition to low serum levels of 25(OH)D and 1,25(OH)₂D, CKD patients may also have dysregulated levels of 24,25-dihydroxyvitamin D (24,25(OH)₂D). 24,25(OH)₂D is the most abundant product of vitamin D catabolism and is produced by the enzyme 24-hydroxylase (CYP24A1) (11). The relative abundance of catabolic vitamin D metabolites such as 24,25(OH)₂D in patients with CKD has yet to be fully defined, but it is important to recognise that decreased availability of substrate 25(OH)D may be exacerbated by the stimulatory effect of FGF23 on CYP24A1 (12). With this in mind, recent research in healthy populations suggest that ratios between vitamin D metabolites may provide a more pathophysiologically relevant insight into the metabolism and function of vitamin D (13). An overview of the chemical structures and hydroxylation steps is shown in Fig. 1.

In this study, we hypothesised that ESRD patients undergoing haemodialysis may benefit from supplementation with vitamin D₃ (cholecalciferol) to elevate serum 25(OH)D levels in addition to conventional active vitamin D analogues. Based on insight into pathways involved in vitamin D metabolism, we postulated that patients with ESRD, when given sufficient substrate, retain the capacity to generate a significant rise in serum levels of 1,25(OH)₂D₃.

Materials and methods

All aspects of the study received National Health Service ethical approval (reference 14/EE/10 and 14/NS/1012). Patients were included if they were established on haemodialysis for ≥1 month (three sessions per week of 3.5–4 h), had no hospital admissions within the past 4 weeks and had no active malignancy. Patients were excluded if they were already taking cholecalciferol or ergocalciferol. All 202 patients having dialysis at University Hospitals Coventry and Warwickshire (UHCW) satellite dialysis centres meeting the inclusion criteria were invited for recruitment; 81 agreed to participate. Cholecalciferol supplementation was given by the nursing staff, during routine dialysis visits, based on serum 25(OH)D levels. Patients received cholecalciferol, 40,000 IU weekly for 12 weeks if serum 25(OH)D was <50 nmol/L, 20,000 IU fortnightly if serum 25(OH)D was 75–150 nmol/L, and cholecalciferol was stopped if serum 25(OH)D was ≥150 nmol/L. Serum 25(OH)D was measured 3 monthly. The aim was to maintain serum 25(OH)D levels between 75 and 150 nmol/L; the lower target of 75 nmol/L is based on the level defined as sufficient by current Endocrine Society guidelines (14). Active analogue dose was recorded at baseline and study end. Serum calcium was measured monthly and PTH concentration 3 monthly as part of usual care. Blood samples were taken by renal research nurses at routine dialysis sessions, processed and stored at −80°C, for subsequent measurement of serum 25(OH)D, 1,25(OH)₂D₃ and 24,25(OH)₂D₃ using liquid chromatography-tandem mass spectrometry (LC-MS/MS) at baseline (T0) and after 12 months supplementation (T1) (using previously described, quality controlled methods) (15). All samples (T0 and T1) were processed for the measurement of vitamin D metabolites at study end; clinicians were blinded to serum 1,25(OH)₂D₃ levels during the study. Doses of active vitamin D analogues were modified according to calcium and PTH levels as part of usual practice. Vitamin D metabolite ratios (VMRs): 1,25(OH)₂D₃:25(OH)D₃, 25(OH)D₃:24,25(OH)₂D₃ and 1,25(OH)₂D₃:24,25(OH)₂D₃ were calculated. Analysis was carried out using the related-samples Wilcoxon signed rank test and Spearman’s rank correlation coefficient to compare data pre- and post-cholecalciferol supplementation.

Results

Complete data for all parameters at T0 and T1 was obtained for 55 of 81 participants. Reasons for
incomplete data were death (n = 15), transplantation (n = 4), change in modality to peritoneal dialysis (n = 1) and haemolysed samples (n = 6). Participants had a median age of 69 (range: 27–76), 50% were male and 93% White. The study population was representative of the local haemodialysis population for all characteristics except for ethnicity; 74% of UHCW haemodialysis patients were White.

Serum levels of all three vitamin D₃ metabolites (25(OH)D₃, 1,25(OH)₂D₃ and 24,25(OH)₂D₃) showed a significant increase from baseline to 12 months following supplementation with cholecalciferol, \( P < 0.001 \) (Fig. 2 and Table 1). This elevation of individual metabolites was associated with a significant reduction in the ratio of 1,25(OH)₂D₃:25(OH)D₃ and 1,25(OH)₂D₃:24,25(OH)₂D₃, \( P = 0.01 \) and \( P = 0.05 \), respectively (Fig. 2 and Table 1). There was no significant change in the ratio of 25(OH)D₃:24,25(OH)₂D₃, \( P = 0.70 \). A significant increase in serum calcium occurred, \( P = 0.001 \). There was no change in serum PTH (Table 1).

**Figure 1**
Vitamin D metabolism – the chemical structures and hydroxylation steps. 25-hydroxylation (25-hydroxylase, CYP2R1) converts vitamin D to 25(OH)D in the liver. 1α-hydroxylation (1α-hydroxylase, CYP27B1) converts 25(OH)D to 1,25(OH)₂D in the kidney. Other tissues contain these enzymes, but the liver is the main source of 25-hydroxylase, and the kidney is considered the main source for 1α-hydroxylase. 1,25(OH)₂D is further metabolised by 24-hydroxylase (24-hydroxylase, CYP24A1) to 1,24,25(OH)₃D. 24-hydroxylase also acts on 25(OH)D to produce 24,25(OH)₂D. The production of these metabolites is considered degradation; expression of 24-hydroxylase and 1α-hydroxylase is reciprocal in order to control 1,25(OH)₂D levels.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
There was no correlation between serum 25(OH)D and 1,25(OH)2D3 at T0 or T1, rho = 0.165, P = 0.23, and rho = 0.180, P = 0.19, respectively. There was also no correlation between serum calcium and serum 25(OH)D at T0 or T1, rho = 0.092, P = 0.10, and rho = 0.106, P = 0.11. Serum 1,25(OH)2D3 did not correlate with calcium at baseline but there was a weak, significant correlation at study end (T1), rho = 0.094, P = 0.50 and rho = 0.288, P = 0.033, respectively. Mean prescribed daily active vitamin D analogue dose reduced from 0.94 at T0 to 0.77 µg at T1 (P = 0.73). Forty-four of 55 patients (80%) were prescribed an active vitamin D analogue at baseline and 41 of 55 (75%) were prescribed an active vitamin D analogue at 12 months. The prescribed dose of active vitamin D analogue reduced during study follow-up in 14 patients, did not change in 25 patients, and increased (or was commenced) in 7 patients. 1-Alfacalcidol accounted 91% of active analogue prescriptions (Table 2).

### Table 1  Calcium, parathyroid hormone, vitamin D metabolites and metabolite ratios at baseline and 12 months.

| Serum level/vitamin D metabolite ratio | Baseline (T0) median (IQR) | 12 months (T1) median (IQR) | Wilcoxon signed-rank test (P) |
|---------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Corrected calcium (mmol/L)            | 2.35 (2.23–2.44)            | 2.39 (2.32–2.52)            | 0.001                       |
| Parathyroid hormone (pmol/L)          | 27.0 (16.0–43.5)            | 29.0 (14.0–42.5)            | 0.81                        |
| 25(OH)D2 (nmol/L)                     | 35.1 (23.0–47.5)            | 119.9 (99.5–143.3)          | <0.001                      |
| 1,25(OH)2D3 (pmol/L)                  | 48.3 (35.9–57.9)            | 96.2 (77.1–130.6)           | <0.001                      |
| 24,25(OH)D2 (nmol/L)                  | 3.8 (2.3–6.0)               | 12.3 (9.6–16.4)             | <0.001                      |
| 1,25(OH)2D3:25(OH)D2                 | 1.2 (0.8–2.1)               | 0.9 (0.6–1.1)               | 0.01                         |
| 25(OH)D2:24,25(OH)D3                  | 9.1 (7.0–12.4)              | 10.3 (8–12.9)               | 0.70                         |
| 1,25(OH)2D3:24,25(OH)D3               | 10.4 (5.8–19.4)             | 7.9 (5.6–11.9)              | 0.05                         |

Serum corrected calcium, parathyroid hormone, 25(OH)D2, 1,25(OH)2D3, and 24,25(OH)D3 were measured at baseline, pre-cholecalciferol supplementation (T0) and again at 12 months (T1), n = 55. A significant increase was seen from T0 to T1 in calcium and all three vitamin D metabolites. Median calcium remained within target range. The was no change in parathyroid hormone levels. A significant reduction in 1,25(OH)2D3:25(OH)D2 and 1,25(OH)2D3:24,25(OH)D3 occurred but no significant change was seen from baseline to 12 months in 25(OH)D2:24,25(OH)D3.

Figure 2  Serum 25(OH)D2, 24,25(OH)D3, 1,25(OH)2D3, and the metabolite ratios 25(OH)D2:24,25(OH)D3, 1,25(OH)2D3:24,25(OH)D3, and 1,25(OH)2D3:25(OH)D2 at baseline and 12 months. Serum 25(OH)D2, 24,25(OH)D3, and 1,25(OH)2D3 were measured using LC-MS/MS and the ratios 25(OH)D2:24,25(OH)D3, 1,25(OH)2D3:24,25(OH)D3, and 1,25(OH)2D3:25(OH)D2 calculated, in patients at baseline, pre-cholecalciferol supplementation (T0), and again at 12 months (T1). (A) Serum 25(OH)D increased: 35.1 nmol/L (23.0–47.5) vs 130.0 nmol/L (99.5–143.3), P < 0.001. (B) Serum 24,25(OH)D3 increased: 3.8 nmol/L (2.3–6.0) vs 12.3 nmol (9.0–16.4), P < 0.001. (C) No significant change in 25(OH)D2:24,25(OH)D3: 9.1 (7.0–12.4) vs 10.3 (8.0–12.9) respectively, P = 0.70. (D) Serum 1,25(OH)2D3 increased: 48.3 pmol/L (35.9–57.9) vs 96.2 pmol/L (77.1–130.6), P < 0.001. (E) 1,25(OH)2D3:24,25(OH)D3 reduced: 10.4 (5.8–19.4) vs 7.9 (5.6–11.9) P = 0.05. (F) 1,25(OH)2D3:25(OH)D2 also reduced: 1.2 (0.8–2.1) vs 0.9 (0.6–1.1), P = 0.01. Wilcoxon signed rank test. Data represent median (IQR), n = 55.
Table 2  Active analogue type and dose at baseline and 12 months.

| Active analogue    | Baseline (µmcg) mean ± s.d. (n) | 12 month (µmcg) mean ± s.d. (n) | Wilcoxon signed-rank test (P) |
|--------------------|----------------------------------|----------------------------------|-----------------------------|
| 1-Alfacalcidol     | 0.76 ± 1.30 (n = 40)             | 0.58 ± 0.95 (n = 37)             | 0.103                       |
| Paricalcitol       | 8.00 (n = 1)                     | 8.00 (n = 1)                     | N/A                         |
| Calcitriol         | 0.92 ± 0.95 (n = 3)              | 0.79 ± 1.05 (n = 3)              | 0.180                       |
| Total combined     | 0.94 ± 1.64 (n = 44)             | 0.77 ± 1.43 (n = 41)             | 0.73                         |

Forty-four of 55 (80%) subjects were prescribed an active analogue at the start of the study. 1-Alfacalcidol accounted for 91% of active analogue prescriptions (40 of 44), three patients were prescribed calcitriol and only one patient was prescribed paricalcitol. There was no significant change in active analogue use during the 12-month study period, n = 55.

Discussion

This is the first study to date, to assess the impact of vitamin D supplementation on the serum vitamin D multi-metabolite profile and vitamin D metabolite ratios in ESRD. One of the pathophysiological consequences of CKD is the reduced renal capacity to synthesise 1,25(OH)₂D, reportedly due to reduced expression of renal CYP27B and concomitant reduction of 1α-hydroxylase activity in the face of elevated levels of FGF23 (6, 12). In the current study, serum 1,25(OH)₂D₃ concentrations were low at baseline (median 48.3 pmol/L, IQR: 35.9–57.9, normal reference range 60–108 pmol/L) (16) despite 80% of patients receiving vitamin D analogues to promote 1,25(OH)₂D activity in the context of elevated PTH levels. This suggests that vitamin D analogues may be utilised immediately rather than being stored in a serum 1,25(OH)₂D pool. A possible explanation for this, yet to be demonstrated in the literature, is that a sudden increase in 1,25(OH)₂D₃ following active analogue administration is met with a catabolic response (by increased 24-hydroxylase activity) in a bid to minimise the risk of hypercalcaemia. This may, in turn, cause 1,25(OH)₂D₃ to be metabolised to its less-active 24-hydroxylated catabolite 1,24,25(OH)₃D₃. This metabolite was not measured in the current study but levels of 24,25(OH)₂D₃ are frequently used as a general marker of 24-hydroxylase activity. In the current study, the circulating levels of 24,25(OH)₂D₃ (3.8 nmol/L, 2.3–6.0 nmol/L) were similar to previously reported serum values for healthy individuals (17). However, this level increased three-fold following vitamin D supplementation highlighting further capacity for 24-hydroxylation of vitamin D metabolites that may rapidly counteract elevation of 1,25(OH)₂D₃ levels following administration of active analogues.

A lack of consensus on optimal serum levels of 25(OH)D has hindered the management of vitamin D deficiency (18, 19). The UK Scientific Advisory Committee on Nutrition (SACN) guidance recommends serum levels of 25(OH)D ≥25 nmol/L, with supplementation advised for those below this level (20). Most of the participants in the current study would, therefore, not have met the SACN criteria for supplementation at baseline. However, prevention of different chronic disease states may require different serum 25(OH)D concentrations (21). Data from the current study suggest that patients with ESRD may need higher serum 25(OH)D to facilitate optimal 1α-hydroxylase activity; in this study, most patients achieved normal serum 1,25(OH)₂D₃ concentration with serum 25(OH)D ≥75 nmol/L (the level defined as sufficient by the Endocrine Society) (14).

Data presented here also indicate that ESRD patients retain a significant capacity for 1α-hydroxylase activity, with synthesis of 1,25(OH)₂D₃ occurring in a substrate (25(OH)D₃)-dependent fashion. Previous studies have also described the potential for synthesis of 1,25(OH)₂D₃ in ESRD patients. Jean et al. demonstrated a rise in serum 1,25(OH)₂D₃ in response to cholecalciferol supplementation but not within the normal reference range (45 ± 13 pmol/L at study end) (22). Patients had lower baseline serum 1,25(OH)₂D₃ than the current study and active vitamin D analogue use was an exclusion criteria (22). Other studies also demonstrated increased serum 1,25(OH)₂D₃ in response to cholecalciferol supplementation, with larger increases seen in patients receiving concomitant alfalcacidol (23). Again, the increased serum 1,25(OH)₂D₃ in these patients did not reach normal range but this could have been due to the short intervention period of 8 weeks (23). Whether cholecalciferol as a sole therapy is sufficient remains unknown; concurrent active analogue therapy is shown to be safe (not associated with increased risk of hypercalcaemia) (24, 25, 26), and may be required to maintain target serum 1,25(OH)₂D₃.

Cholecalciferol supplementation increases the inactive substrate 25(OH)D rather than directly increasing 1,25(OH)₂D. Increase in serum 25(OH)D and 24,25(OH)₂D₃ are disproportionate to 1,25(OH)₂D₃ increase, demonstrating the known tight regulation of 1,25(OH)₂D₃ synthesis and secretion (in response to calcium and parathyroid hormone) (27). Therefore optimising
25(OH)D through cholecalciferol supplementation will not result in unlimited 1,25(OH)₂D and severe hypercalcaemia. An increase in median calcium was seen in this study, but this was not clinically relevant. In addition, the absence of correlation between calcium and 25(OH)D, and 1,25(OH)₂D and 25(OH)D, supports the documented safety of cholecalciferol supplementation in ESRD (28, 29). Other studies have reported no change in serum calcium in response to cholecalciferol supplementation (23, 24, 25, 26, 30).

Metabolite ratios have been shown to be useful markers of altered vitamin D metabolism. For example a high 1,25(OH)₂D:25(OH)D ratio can help diagnose sarcoidosis and a high 25(OH)D:24,25(OH)D ratio can be used to diagnose loss of CYP24A1 (24-hydroxylase) function (31, 32, 33, 34). The metabolite ratio offers insight above that of a single metabolite measurement; a low 24,25(OH)D:25(OH)D could simply reflect low 25(OH)D whereas a high 25(OH)D:24,25(OH)D ratio is a viable marker of altered 24-hydroxylase activity (31). A moderate elevation of 25(OH)D:24,25(OH)D due to reduced activity of 24-hydroxylase is seen in CKD and bone disorders (35, 36, 37). Evidence suggests the value of using 25(OH)D:24,25(OH)D in assessment and management of both fracture risk and CKD risk (38, 39). Serum 1,25(OH)₂D is not routinely measured clinically (40, 41); yet in ESRD 1,25(OH)₂D deficiency is routinely assumed, and active analogue treatment is routinely prescribed (42). A low serum 1,25(OH)₂D in the presence of a high 1,25(OH)₂D:25(OH)D ratio would indicate that 25(OH)D is limiting synthesis and secretion of 1,25(OH)₂D, suggesting that treatment could include serum 25(OH)D repletion. Results here support the findings of Tang and colleagues who reported an inverse correlation between 1,25(OH)₂D:24,25(OH)D and serum 25(OH)D in healthy young adults (13). Data suggest sufficient serum 25(OH)D provides for maintenance of 1,25(OH)₂D and 24,25(OH)D in relative proportion (within the normal range). In contrast, when 25(OH)D is lacking, 1,25(OH)₂D:24,25(OH)D increases as the production of serum 1,25(OH)₂D is prioritised over 24,25(OH)D. Therefore, it appears that, in the presence of low 25(OH)D, the 24,25(OH)₂D pathway is partially inactivated to conserve 25(OH)D for production of 1,25(OH)₂D. The same study also demonstrated that low 25(OH)D (<50 nmol/L), normal 1,25(OH)₂D and high 1,25(OH)₂D:24,25(OH)D was associated with a significantly higher serum PTH (13). It is anticipated that treatment with active analogues, for suppression of PTH, would increase the 1,25(OH)₂D:24,25(OH)D and, therefore, may be counterproductive. Whereas treatment focusing on optimising 25(OH)D would induce 1α-hydroxylase and 24-hydroxylase, increasing 1,25(OH)₂D and 24,25(OH)D in a regulated fashion, in turn reducing the 1,25(OH)₂D:24,25(OH)D ratio; as shown here. Measurement of vitamin D metabolites and calculation of the metabolite ratios could, therefore, offer insight into the prevention and management of SHPT in CKD. Serum PTH did not change in this study but this may be due to established secondary hyperparathyroidism in this patient cohort which results in parathyroid hyperplasia reducing sensitivity to calcium and 1,25(OH)₂D through downregulation of vitamin D receptors and calcium sensing receptors (43, 44). Optimisation of serum 25(OH)D earlier in the progression of CKD may delay the onset, and minimise the severity, of secondary hyperparathyroidism (10). The recognition for the need to treat 25(OH)D deficiency in the management of secondary hyperparathyroidism has grown in recent years, yet in ESRD the emphasis has remained on active analogue treatment (42).

Prescribers have historically promoted active vitamin D analogues to circumvent apparent lack of 1α-hydroxylase activity (and associated 1,25(OH)₂D levels) in ESRD yet results here demonstrate otherwise. By their very nature, active vitamin D analogues promote hypercalcaemia. Cholecalciferol is safer and may provide for management of both 25(OH)D and 1,25(OH)₂D deficiencies. Is it time to approach vitamin D deficiency in CKD differently by supplementing the substrate and, if indicated by suboptimal serum PTH response, adding in the active analogue? For example, analogous to the management of anaemia where it is routine to administer iron loading initially before concluding a lack of erythropoietin. The focus on active vitamin D analogues for the treatment of 1,25(OH)₂D deficiency in ESRD not only overlooks 25(OH)D deficiency, but also vitamin D metabolism as a whole. This risks patients' missing out on potential non-bone, as well as bone related benefits of serum 25(OH)D (45, 46, 47, 48).

This study is limited by the absence of a control group, so a randomised controlled trial is required to: (i) confirm findings; (ii) explore potential clinical benefits of cholecalciferol repletion; (iii) investigate whether concurrent active analogue therapy is required or whether cholecalciferol is effective as a sole treatment (can calcium and parathyroid hormone levels remain stable without the need for an active vitamin analogue in ESRD?). Whilst research is steering towards more comprehensive analysis of metabolites (49, 50), at present the clinical usefulness of the multi-metabolite assay in ESRD requires further research.
and measurement of serum 25(OH)D concentration remains the sole marker of vitamin D status (14). The results presented here offer new insight into vitamin D metabolism in ESRD, specifically demonstrating that haemodialysis patients retain the capacity to significantly increase serum 1,25(OH)₂D₃. Conventional oral vitamin D (cholecalciferol) supplementation may, therefore, provide a cheap and safe strategy for the management of vitamin D homeostasis in ESRD patients.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported in part by a grant from the British Renal Society and Kidney Patient Association, and the UK CRN (Study ID numbers: 17213 and 17275).

Consent
Consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures.

References
1. Brunette MG, Chan M, Ferriere C & Roberts KD. Site of 1,25(OH)₂ vitamin D₃ synthesis in the kidney. Nature 1978 286 287–289. (https://doi.org/10.1038/276287a0)
2. Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, Heslop M & Stewart PM. Expression of 25-hydroxyvitamin D-1α-hydroxylase in the human kidney. Journal of the American Society of Nephrology 1999 10 2465–2473. (https://doi.org/10.1681/ASN.1999122465)
3. Haussler CA & Jurutka PW. The role of vitamin D in the FGF23, klotho, vitamin D receptor, and phosphate bone- kidney endocrine axis. Reviews in Endocrine and Metabolic Disorders 2012 13 57–69. (https://doi.org/10.1007/s11554-011-9199-8)
4. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM & Heslop M. Extrarenal expression of 25-hydroxyvitamin D₃-1α-hydroxylase. Journal of Clinical Endocrinology and Metabolism 2001 86 888–894. (https://doi.org/10.1210/jcem.86.2.7220)
5. Zehnder D, Evans KN, Kilby MD, Bulmer JN, Innes BA, Stewart PM & Heslop M. The ontogeny of 25-hydroxyvitamin D₃ 1α-hydroxylase expression in human placenta and decidua. American Journal of Pathology 2002 161 105–114. (https://doi.org/10.1016/s0002-9440(01)64162-4)
6. Levin A, Bakris GL, Moltch M, Smulemers M, Tian J, Williams LA & Andres DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International 2007 71 31–38. (https://doi.org/10.1038/sj.ki.5002009)
7. Craver L, Marco MF, Martínez-I, Rue M, Borràs M, Martín ML, Sarró E, Valdivielso JM & Fernández E. Mineral metabolism parameters throughout chronic kidney disease stages 1–5 – achievement of K/DOQI target ranges. Nephrology, Dialysis, Transplantation 2007 22 1171–1176. (https://doi.org/10.1093/ndt/gfl718)
8. Saab G, Young DO, Gincherman Y, Giles K, Norwood K & Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron: Clinical Practice 2007 105 c132–c138. (https://doi.org/10.1159/000098645)
9. Huish SA, Fletcher S, Dunn JA, Hewison M & Bland R. Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry. Journal of Steroid Biochemistry and Molecular Biology 2016 164 214–217. (https://doi.org/10.1016/j.jsbm.2016.02.009)
10. Jean G, Vanel T, Terrac JC & Chazot C. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation. Hemodialysis International 2010 14 486–491. (https://doi.org/10.10111/j.1542-4588.2010.00472.x)
11. St-Arnaud R & Chapter G. Chapter 6 – CYP24A1: structure, function, and physiological role. In Vitamin D (Fourth Edition), pp. 81–95. Academic Press, 2018. (https://doi.org/10.1016/B978-0-12-809965-0.00006-9)
12. Quailes LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Experimental Cell Research 2012 318 1040–1048. (https://doi.org/10.1016/j.yexcr.2012.02.027)
13. Tang JC, Jackson S, Walsh NJ, Greeses J & Fraser WD. The dynamic relationships between the active and catabolic vitamin D metabolites, their ratios, and associations with PTH. Scientific Reports 2019 9 1–10. (https://doi.org/10.1038/s41598-019-43462-6)
14. Hollick ME, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM & Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 1911–1930. (https://doi.org/10.1210/jc.2011-0385)
15. Jenkinson C, Taylor AE, Hassan-Smith ZK, Adams JS, Stewart PM, Hewison M & Keevil BG. High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum. Journal of Chromatography: B, Analytical Technologies in the Biomedical and Life Sciences 2016 1018 56–63. (https://doi.org/10.1016/j.jchromb.2016.01.049)
16. Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nature Reviews: Endocrinology 2017 13 466–479. (https://doi.org/10.1038/nrendo.2017.31)
17. Hassan-Smith ZK, Jenkinson C, Smith DJ, Hernandez I, Morgan SA, Crabtree NJ, Gittoes NJ, Kevil BG, Stewart PM & Hewison M. 25-Hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ exert distinct effects on human skeletal muscle function and gene expression. PLoS ONE 2012 17 e0170665. (https://doi.org/10.1371/journal.pone.0170665)
18. Heaney RP. What is vitamin D insufficiency? And does it matter? Calcified Tissue International 2013 92 177–183. (https://doi.org/10.1007/s00223-012-9605-6)
19. Rosen CJ & Taylor CL. Common misconceptions about vitamin D – implications for clinicians. Nature Reviews: Endocrinology 2013 9 434–438. (https://doi.org/10.1038/nrendo.2013.75)
20. Scientific Advisory Committee on Nutrition (SACN). SACN vitamin D and health report, 2016. (available at: https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report)
21. Muscogiuri G. Vitamin D: past, present and future perspectives in the prevention of chronic diseases. European Journal of Clinical Nutrition 2018 72 1221–1225. (https://doi.org/10.1038/s41430-018-0261-4)
22. Jean G, Soubrier-Bielle JC & Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrology, Dialysis, Transplantation 2009 24 3799–3805. (https://doi.org/10.1093/ndt/gfp370)
23. Markmann JF, Angerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jepsersen J, Nybo M, Rasmussen LM, Hansen D & Scholze A. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrology, Dialysis, Transplantation 2012 27 3523–3531. (https://doi.org/10.1093/ndt/gfs138)
24. Mose FH, Vase H, Larsen T, Kancir AS, Kosierkiewicz R, Jonczy B, Hansen AB, Oczaczowska-Kulik AE, Thomsen IM, Bech JN, et al.
Cardiovascular effects of cholecalciferol treatment in dialysis patients – a randomized controlled trial. BMC Nephrology 2014 15 50. (https://doi.org/10.1186/1471-2369-15-50)

25 Delaney P, Weekers L, Warling X, Moonen M, Smelten N, Medart L, Krzesinski JM & Cavalier E. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrology, Dialysis, Transplantation 2013 28 1779–1786. (https://doi.org/10.1093/ndt/gft001)

26 Selbert E, Heine GH, Ulrich C, Seiler S, Kohler H & Girndt M. Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: a randomized, double-blind, placebo-controlled clinical trial. Neplon: Clinical Practice 2013 123 209–219. (https://doi.org/10.1159/000354717)

27 Bland R. Calcium homeostasis and bones. In Seibert E, Heine GH, Ulrich C, Seiler S, Kohler H & Girndt M. Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: a randomized, double-blind, placebo-controlled clinical trial. Neplon: Clinical Practice 2013 123 209–219. (https://doi.org/10.1159/000354717)

28 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. American Journal of Clinical Nutrition 1999 69 842–856. (https://doi.org/10.1093/ajcn/69.5.842)

29 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the tolerable upper intake level of vitamin D. EFSA Journal 2012 10 2813. (https://doi.org/10.2903/j.efsa.2012.2813)

30 Armas LA, Andukuri R, Barger-Lux J, Heaney RP & Lund R. 25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clinical Journal of the American Society of Nephrology 2012 7 1428–1434. (https://doi.org/10.2215/CJN.12761211)

31 Kowalska E, Rola R, Wojcik M, Laszcz N, Phudowski P, Wierzbicka A, Janiec A, Książyk J, Halat P, Clara E, et al. Analysis of vitamin D3 metabolites in survivors of infantile idiopathic hypercalcaemia caused by CYP24A1 mutation or SLC34A1 mutation. Journal of Steroid Biochemistry and Molecular Biology 2021 208 105824. (https://doi.org/10.1016/j.jsbmb.2021.105824)

32 Rohmer J, Hadjadji J, Bouzeraa A, Salah S, Paule R, Groh M, Blanche P, Mouton L, Monnet D, Le Jeune C, et al. Serum 1,25(OH)2 vitamin D and 25(OH) vitamin D ratio for the diagnosis of sarcoidosis-related uveitis. Ocular Immunology and Inflammation 2020 28 341–347. (https://doi.org/10.1080/09273948.2018.1537399)

33 Hilderson I, Van Laecke S, Wauters A & Donck J. Treatment of chronic sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrology, Dialysis, Transplantation 2014 29 1841–1847. (https://doi.org/10.1093/ndt/gfu142)

34 Dinour D, Beckerman P, Ganon L, Fordman K, Eisenstein Z & Holtzman EJ. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalcicuric nephrolithiasis and nephrocalcinosis. Journal of Urology 2013 190 S52–S57. (https://doi.org/10.1016/j.juro.2013.02.1188)

35 Bosworth CR, Levin G, Robinson-Cohen C, Hoofnagle AN, Ruzinski J, Young B, Schwartz SM, Himmelfarb J, Kestenbaum B & de Boer IH. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney International 2012 82 693–700. (https://doi.org/10.1038/ki.2012.193)

36 Stubbs JR, Zhang S, Friedman PA & Nolin TD. Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD. Clinical Journal of the American Society of Nephrology 2014 9 1965–1973. (https://doi.org/10.2215/CJN.03103314)

37 Edouard T, Hussein A, Giorieux FH & Rauch F. Serum 24,25-dihydroxyvitamin D concentrations in osteogenesis imperfecta: relationship to bone parameters. Journal of Clinical Endocrinology and Metabolism 2012 97 1243–1249. (https://doi.org/10.1210/jc.2011-3015)

38 Figureus ML, Linglart A, Bienaimé F, Allain-Launay E, Roussy-Kessler G, Ryckwaert A, Kottler ML & Hourmant M. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. American Journal of Kidney Diseases 2015 65 122–126. (https://doi.org/10.1016/j.ajkd.2014.06.037)

39 Ginsberg C, Katz R, de Boer IH, Kestenbaum B, Chonchol M, Shlipak MG, Sarnak MJ, Hoofnagle AN, Rifkin DE, Garimella PS, et al. The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: the cardiovascular health study. Bone 2018 107 124–130. (https://doi.org/10.1016/j.bone.2017.11.011)

40 Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. Journal of Bone and Mineral Research 2007 22 1668–1671. (https://doi.org/10.1359/jbmr.070716)

41 Webb AR. Who, where and when – influences on cutaneous vitamin D synthesis. Progress in Biophysics and Molecular Biology 2006 92 17–25. (https://doi.org/10.1016/j.pbiomolbio.2006.02.004)

42 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International Supplements 2017 1 1–59. (https://doi.org/10.1016/j.kisu.2017.04.001)

43 Slatopolsky E, Brown A & Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney International: Supplement 1999 73 S14–S19. (https://doi.org/10.1046/j.1523-1755.1999.07304.x)

44 Brown EM, Wilson RE, Eastman RC, Pallotta J & Marynick SP. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. Journal of Clinical Endocrinology and Metabolism 1982 54 172–179. (https://doi.org/10.1210/jcem-54-1-172)

45 Boudville N, Inderjeeth C, Elder GJ & Glendenning P. Association between 25-hydroxyvitamin D, somatic muscle weakness and falls risk in end-stage renal failure. Clinical Endocrinology 2010 73 299–304. (https://doi.org/10.1111/j.1365-2265.2010.03821.x)

46 Kiss Z, Ambres C, Almasi C, Berta K, Deak G, Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron: Clinical Practice 2011 117 c373–c378. (https://doi.org/10.1159/000321521)

47 Srisukul U, Gilmartin C, Akkina S & Porter A. 302 Effects of vitamin D repletion on hemoglobin and the dose of an erythropoiesis stimulating agent. American Journal of Kidney Diseases 2011 57 A92. (https://doi.org/10.1053/j.ajkd.2011.02.305)

48 Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J & Ferreira A. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clinical Journal of the American Society of Nephrology 2010 5 905–911. (https://doi.org/10.2215/CJN.06100909)

49 Tuckey RC, Cheng CYS & Slominski AT. The serum vitamin D metabolome: what we know and what is still to discover. Journal of Steroid Biochemistry and Molecular Biology 2019 186 4–21. (https://doi.org/10.1016/j.jsbmb.2018.09.003)

50 Jenkinson C. The vitamin D metabolome: an update on analysis and function. Cell Biochemistry and Function 2019 37 408–423. (https://doi.org/10.1002/cbf.3421)